Controlled release pharmaceutical compositions of galantamine
The controlled release pharmaceutical compositions of Galantamine using matrix mini tablets with water-soluble or insoluble materials address the complexity and cost issues of existing formulations, offering a cost-effective, stable, and bioequivalent once-a-day administration with reduced side effects and improved patient compliance.
Patent Information
- Application Number
- PCT/IN2010/000767
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2009-11-26
- Filing Date
- 2010-11-26
- Publication Date
- 2011-06-03
AI Technical Summary
Existing controlled release formulations of Galantamine are costly and complex, with multiple step processes that increase production costs and render the product expensive, while also leading to side effects associated with immediate release dosage forms.
Development of controlled release pharmaceutical compositions comprising matrix mini tablets with Galantamine hydrobromide and pharmaceutically acceptable additives, which can be filled into empty capsule shells, utilizing water-soluble, insoluble, or swellable materials as release modifying agents without a rate controlling coating, to achieve a controlled release profile.
The solution provides a cost-effective, easy-to-prepare controlled release form with improved patient compliance, reduced side effects, and a reliable release rate for Galantamine, allowing once-a-day administration with a desired drug release profile similar to marketed products like Reminyl XL®, while maintaining stability and bioequivalence.